[{"id":"0b1a6a31-b42a-439f-983a-b576150910a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326464","created_at":"2022-04-13T11:55:14.092Z","updated_at":"2024-07-02T16:35:24.087Z","phase":"Phase 3","brief_title":"Tofacitinib in Recurrent GBM Patients","source_id_and_acronym":"NCT05326464","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR amplification • IDH wild-type","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-09"},{"id":"f384c94c-4626-4812-85bd-523c626b0875","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034238","created_at":"2021-01-18T19:47:53.888Z","updated_at":"2024-07-02T16:35:41.280Z","phase":"Phase 1","brief_title":"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors","source_id_and_acronym":"NCT04034238","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib • LMB-100"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 11/19/2021","study_completion_date":" 11/19/2021","last_update_posted":"2023-08-01"},{"id":"3f3f4ef8-0bd9-4dcd-bf2a-d11ae95d4356","acronym":"","url":"https://clinicaltrials.gov/study/NCT04768504","created_at":"2021-02-24T13:59:53.730Z","updated_at":"2024-07-02T16:35:44.900Z","phase":"Phase 2","brief_title":"Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study","source_id_and_acronym":"NCT04768504","lead_sponsor":"Khashayar Esfahani","biomarkers":" PD-L1 • PD-1 • CTLA4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 09/25/2025","study_completion_date":" 09/25/2025","last_update_posted":"2023-06-23"}]